U.S. markets open in 8 hours 56 minutes
  • S&P Futures

    4,216.25
    +6.50 (+0.15%)
     
  • Dow Futures

    33,343.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    13,341.75
    +30.50 (+0.23%)
     
  • Russell 2000 Futures

    1,980.20
    +3.90 (+0.20%)
     
  • Crude Oil

    93.81
    -0.53 (-0.56%)
     
  • Gold

    1,807.30
    +0.10 (+0.01%)
     
  • Silver

    20.33
    -0.01 (-0.07%)
     
  • EUR/USD

    1.0321
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2194
    -0.0008 (-0.07%)
     
  • USD/JPY

    133.1680
    +0.1690 (+0.13%)
     
  • BTC-USD

    23,986.97
    -325.75 (-1.34%)
     
  • CMC Crypto 200

    570.17
    -4.57 (-0.80%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,504.51
    +685.18 (+2.46%)
     

Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Angion Biomedica Corp (NASDAQ: ANGNhas discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

  • The trial began enrolling patients in December 2021.

  • A reassessment was conducted following a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial's drug treatment arm.

  • Related: Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So

  • "Based on our ongoing analysis of the risk/benefit profile of ANG-3070 in patients with primary proteinuric kidney disease, we believe it to be in the best interest of patients to discontinue our Phase 2 JUNIPER study at this time..," stated CEO Jay Venkatesan.

  • Angion expects to report more than $60 million in cash and cash equivalents at the end of Q2.

  • In April, the company decided to discontinue the development of ANG-3777 after disappointing data.

  • Price Action: ANGN shares closed 18.7% lower at $1.39 during after-hours trading on Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.